# Bioharvest Sciences Inc.: overview BHST · Nasdaq · CIK 1723464 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bhst.md) · [Financials](/companies/bhst/financials.md) · [Filings](/companies/bhst/filings.md) · [Insiders](/companies/bhst/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [12.7](/filings/0001376474-25-000299.md) | [25.2](/filings/0001376474-26-000257.md) | [34.5](/filings/0001376474-26-000257.md) | | Gross margin | % | [44.5%](/filings/0001376474-25-000299.md) | [55.4%](/filings/0001376474-26-000257.md) | [59.3%](/filings/0001376474-26-000257.md) | | Operating margin | % | [(78.6%)](/filings/0001376474-25-000299.md) | [(27.7%)](/filings/0001376474-26-000257.md) | [(16.2%)](/filings/0001376474-26-000257.md) | | Net margin | % | [(99.1%)](/filings/0001376474-25-000299.md) | [(51.3%)](/filings/0001376474-26-000257.md) | [(32.3%)](/filings/0001376474-26-000257.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | | Free cash flow | $m | [(10.0)](/filings/0001376474-25-000299.md) | [(9.5)](/filings/0001376474-26-000257.md) | [(9.6)](/filings/0001376474-26-000257.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bhst/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $1.7m | 581,441 | | Reduced −175,623 | | [Evercore Wealth Management, LLC](/funds/1482689.md) | 2026-06-30 | $618.7k | 216,343 | | Added +76,873 | | [True North Advisors, LLC](/funds/1634556.md) | 2026-06-30 | $535.7k | 187,318 | | Added +19,305 | | [Magnus Financial Group LLC](/funds/1765216.md) | 2026-06-30 | $257.4k | 90,000 | | Added +35,000 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $179.5k | 63,658 | | Added +47,264 | | [Silverberg Bernstein Capital Management LLC](/funds/2007880.md) | 2026-06-30 | $162.8k | 57,723 | | Added +31,624 | | [KING LUTHER CAPITAL MANAGEMENT CORP](/funds/310051.md) | 2026-06-30 | $114.4k | 40,000 | | Unchanged | | [TD Waterhouse Canada Inc.](/funds/1999606.md) | 2026-06-30 | $65.5k | 23,827 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $58.2k | 20,652 | | Added +5,899 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $37.3k | 13,232 | | Reduced −16,417 | ## Recent filings [All 135 filings](/companies/bhst/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 16:53 ET | [6-K](/filings/0001723464-26-000060.md) | Report of a foreign private issuer, period 2026-10-13 | 0001723464-26-000060 | | 2026-10-08 | 14:31 ET | [6-K](/filings/0001723464-26-000058.md) | Report of a foreign private issuer, period 2026-10-08 | 0001723464-26-000058 | | 2026-10-02 | 18:10 ET | [6-K](/filings/0001723464-26-000056.md) | Report of a foreign private issuer, period 2026-10-01 | 0001723464-26-000056 | | 2026-09-15 | 17:07 ET | [6-K](/filings/0001723464-26-000054.md) | Report of a foreign private issuer, period 2026-09-15 | 0001723464-26-000054 | | 2026-09-15 | 17:05 ET | [6-K](/filings/0001723464-26-000052.md) | Report of a foreign private issuer, period 2026-09-15 | 0001723464-26-000052 | | 2026-09-14 | 17:05 ET | [6-K](/filings/0001723464-26-000050.md) | Report of a foreign private issuer, period 2026-09-14 | 0001723464-26-000050 | | 2026-09-03 | 15:21 ET | [6-K](/filings/0001723464-26-000048.md) | Report of a foreign private issuer, period 2026-09-03 | 0001723464-26-000048 | | 2026-08-12 | 17:41 ET | [6-K](/filings/0001723464-26-000046.md) | Report of a foreign private issuer, period 2026-08-11 | 0001723464-26-000046 | | 2026-08-11 | 17:40 ET | [6-K](/filings/0001723464-26-000044.md) | Report of a foreign private issuer, period 2026-08-11 | 0001723464-26-000044 | | 2026-07-29 | 16:04 ET | [6-K](/filings/0001723464-26-000042.md) | Report of a foreign private issuer, period 2026-07-29 | 0001723464-26-000042 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001376474-26-000257.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1723464 - Tickers: BHST - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:46 ET. No prices; not investment advice.